RYTM (Rhythm Pharmaceuticals) 3-Year Revenue Growth Rate : 221.80% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals 3-Year Revenue Growth Rate?

Rhythm Pharmaceuticals's Revenue per Share for the three months ended in Dec. 2024 was $0.68.

During the past 12 months, Rhythm Pharmaceuticals's average Revenue per Share Growth Rate was 58.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 221.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 10 years, the highest 3-Year average Revenue per Share Growth Rate of Rhythm Pharmaceuticals was 221.80% per year. The lowest was 221.80% per year. And the median was 221.80% per year.

Competitive Comparison of Rhythm Pharmaceuticals's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Rhythm Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rhythm Pharmaceuticals's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's 3-Year Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

Rhythm Pharmaceuticals 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Rhythm Pharmaceuticals (NAS:RYTM) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Rhythm Pharmaceuticals 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhythm Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (NAS:RYTM) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

1RV:Germany 1RV:Germany

Address

222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116

Website

https://www.rhythmtx.com

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Executives

Pamela J. Cramer	officer: Chief Human Resources Officer	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Yann Mazabraud	officer: EVP, Head of International	C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
Christopher Paul German	officer: Corporate Controller & CAO	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Joseph Shulman	officer: Chief Technical Officer	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Hunter C Smith	officer: CFO and Treasurer	C/O GENESEE & WYOMING INC., 20 WEST AVENUE, DARIEN CT 06820
Jennifer Chien	officer: EVP, Head of North America	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
David P Meeker	director	C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Jennifer L Good	director	15 GREAT RING ROAD, SANDY HOOK CT 06482
Lynn A. Tetrault	director	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
William T. Roberts	officer: Chief Accounting Officer	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Linda Shapiro Manning	officer: Chief Medical Officer	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Todd Foley	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Camille L Bedrosian	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nithya Desikan	officer: Chief Commercial Officer	82 BAY STATE ROAD, BELMONT MA 02478